{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:21:43Z","timestamp":1786980103871,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03623-8","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T09:36:03Z","timestamp":1733996163000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Racial disparities in length of hospitalization and systemic medication utilization in patients with psoriasis"],"prefix":"10.1007","volume":"317","author":[{"given":"Rini","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chase","family":"Irwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"McCune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"issue":"1","key":"3623_CR1","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jaad.2020.01.045","volume":"83","author":"P Singh","year":"2020","unstructured":"Singh P, Silverberg JI (2020) Real-world trends in biologic, oral systemic, and phototherapy in US patients with psoriasis or psoriatic arthritis. J Am Acad Dermatol 83(1):256\u2013257. https:\/\/doi.org\/10.1016\/j.jaad.2020.01.045","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"3623_CR2","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1080\/09546634.2018.1443200","volume":"29","author":"MLF Knuckles","year":"2018","unstructured":"Knuckles MLF, Levi E, Soung J (2018) Defining and treating moderate plaque psoriasis: a dermatologist survey. J Dermatol Treat 29(7):658\u2013663. https:\/\/doi.org\/10.1080\/09546634.2018.1443200","journal-title":"J Dermatol Treat"},{"issue":"5","key":"3623_CR3","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1155\/MI.2005.273","volume":"2005","author":"O Arican","year":"2005","unstructured":"Arican O, Aral M, Sasmaz S, Ciragil P (2005) Serum levels of tnf- \u03b1, ifn- \u03b3, il-6, il-8, il-12, il-17, and il-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005(5):273\u2013279. https:\/\/doi.org\/10.1155\/MI.2005.273","journal-title":"Mediators Inflamm"},{"issue":"11","key":"3623_CR4","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1038\/jid.2012.184","volume":"132","author":"M Su\u00e1rez-Fari\u00f1as","year":"2012","unstructured":"Su\u00e1rez-Fari\u00f1as M, Li K, Fuentes-Duculan J, Hayden K, Brodmerkel C, Krueger JG (2012) Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Investig Dermatol 132(11):2552\u20132564. https:\/\/doi.org\/10.1038\/jid.2012.184","journal-title":"J Investig Dermatol"},{"key":"3623_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/819149","volume":"2015","author":"PSSD Oliveira","year":"2015","unstructured":"Oliveira PSSD, Cardoso PRG, Lima EVDA et al (2015) Il-17a, il-22, il-6, and il-21 serum levels in plaque-type psoriasis in brazilian patients. Mediators Inflamm 2015:1\u20135. https:\/\/doi.org\/10.1155\/2015\/819149","journal-title":"Mediators Inflamm"},{"issue":"3","key":"3623_CR6","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","volume":"139","author":"F Kolbinger","year":"2017","unstructured":"Kolbinger F, Loesche C, Valentin MA et al (2017) \u03b2-Defensin 2 is a responsive biomarker of IL-17A\u2013driven skin pathology in patients with psoriasis. J Allergy Clin Immunol 139(3):923-932.e8. https:\/\/doi.org\/10.1016\/j.jaci.2016.06.038","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"3623_CR7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","volume":"76","author":"J Takeshita","year":"2017","unstructured":"Takeshita J, Grewal S, Langan SM et al (2017) Psoriasis and comorbid diseases. J Am Acad Dermatol 76(3):377\u2013390. https:\/\/doi.org\/10.1016\/j.jaad.2016.07.064","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"3623_CR8","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/bjd.18245","volume":"182","author":"NJ Korman","year":"2020","unstructured":"Korman NJ (2020) Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol 182(4):840\u2013848. https:\/\/doi.org\/10.1111\/bjd.18245","journal-title":"Br J Dermatol"},{"issue":"5","key":"3623_CR9","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","volume":"139","author":"E von Stebut","year":"2019","unstructured":"von Stebut E, Reich K, Tha\u00e7i D et al (2019) Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Investig Dermatol 139(5):1054\u20131062. https:\/\/doi.org\/10.1016\/j.jid.2018.10.042","journal-title":"J Investig Dermatol"},{"issue":"4","key":"3623_CR10","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/cvr\/cvz009","volume":"115","author":"YA Elnabawi","year":"2019","unstructured":"Elnabawi YA, Dey AK, Goyal A et al (2019) Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res 115(4):721\u2013728. https:\/\/doi.org\/10.1093\/cvr\/cvz009","journal-title":"Cardiovasc Res"},{"issue":"6","key":"3623_CR11","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/ijd.14246","volume":"58","author":"SB Kaushik","year":"2019","unstructured":"Kaushik SB, Lebwohl MG (2019) Review of safety and efficacy of approved systemic psoriasis therapies. Int J Dermatol 58(6):649\u2013658. https:\/\/doi.org\/10.1111\/ijd.14246","journal-title":"Int J Dermatol"},{"issue":"3","key":"3623_CR12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.1365-2133.2008.08732.x","volume":"159","author":"J Schmitt","year":"2008","unstructured":"Schmitt J, Zhang Z, Wozel G, Meurer M, Kirch W (2008) Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 159(3):513\u2013526. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08732.x","journal-title":"Br J Dermatol"},{"issue":"4","key":"3623_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.5021\/ad.21.151","volume":"35","author":"S Choi","year":"2023","unstructured":"Choi S, Oh S, Yoon HS (2023) Trends in systemic psoriasis treatment: is psoriasis still being undertreated? Ann Dermatol 35(4):321\u2013324. https:\/\/doi.org\/10.5021\/ad.21.151","journal-title":"Ann Dermatol"},{"issue":"10","key":"3623_CR14","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1001\/jamadermatol.2013.5264","volume":"149","author":"AW Armstrong","year":"2013","unstructured":"Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG (2013) Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the united states: findings from the national psoriasis foundation surveys, 2003\u20132011. JAMA Dermatol 149(10):1180\u20131185. https:\/\/doi.org\/10.1001\/jamadermatol.2013.5264","journal-title":"JAMA Dermatol"},{"issue":"6","key":"3623_CR15","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jaad.2007.06.042","volume":"57","author":"EJ Horn","year":"2007","unstructured":"Horn EJ, Fox KM, Patel V, Chiou CF, Dann F, Lebwohl M (2007) Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol 57(6):957\u2013962. https:\/\/doi.org\/10.1016\/j.jaad.2007.06.042","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"3623_CR16","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s10067-014-2763-3","volume":"34","author":"GS Kerr","year":"2015","unstructured":"Kerr GS, Qaiyumi S, Richards J et al (2015) Psoriasis and psoriatic arthritis in African-American patients\u2013the need to measure disease burden. Clin Rheumatol 34(10):1753\u20131759. https:\/\/doi.org\/10.1007\/s10067-014-2763-3","journal-title":"Clin Rheumatol"},{"issue":"12","key":"3623_CR17","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1038\/jid.2015.296","volume":"135","author":"J Takeshita","year":"2015","unstructured":"Takeshita J, Gelfand JM, Li P et al (2015) Psoriasis in the us medicare population: prevalence, treatment, and factors associated with biologic use. J Invest Dermatol 135(12):2955\u20132963. https:\/\/doi.org\/10.1038\/jid.2015.296","journal-title":"J Invest Dermatol"},{"issue":"1","key":"3623_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/bjd.19876","volume":"185","author":"WT Hodges","year":"2021","unstructured":"Hodges WT, Bhat T, Raval NS et al (2021) Biologics utilization for psoriasis is lower in black compared with white patients. Br J Dermatol 185(1):207\u2013209. https:\/\/doi.org\/10.1111\/bjd.19876","journal-title":"Br J Dermatol"},{"issue":"8","key":"3623_CR19","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s00296-023-05322-5","volume":"43","author":"Y Ross","year":"2023","unstructured":"Ross Y, Jaleel S, Magrey M (2023) Racial disparities in comorbidities of patients with psoriatic arthritis. Rheumatol Int 43(8):1525\u20131529. https:\/\/doi.org\/10.1007\/s00296-023-05322-5","journal-title":"Rheumatol Int"},{"issue":"8","key":"3623_CR20","first-page":"866","volume":"10","author":"SK Shah","year":"2011","unstructured":"Shah SK, Arthur A, Yang YC, Stevens S, Alexis AF (2011) A retrospective study to investigate racial and ethnic variations in the treatment of psoriasis with etanercept. J Drugs Dermatol 10(8):866\u2013872","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"3623_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jaad.2016.03.048","volume":"75","author":"DY Hsu","year":"2016","unstructured":"Hsu DY, Gordon K, Silverberg JI (2016) The inpatient burden of psoriasis in the United States. J Am Acad Dermatol 75(1):33\u201341. https:\/\/doi.org\/10.1016\/j.jaad.2016.03.048","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"3623_CR22","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1007\/s40615-022-01282-x","volume":"10","author":"E Akuffo-Addo","year":"2023","unstructured":"Akuffo-Addo E, Udounwa T, Chan J, Cauchi L (2023) Exploring biologic treatment hesitancy among black and indigenous populations in canada: a review. J Racial Ethn Health Disparities 10(2):942\u2013951. https:\/\/doi.org\/10.1007\/s40615-022-01282-x","journal-title":"J Racial Ethn Health Disparities"},{"issue":"8","key":"3623_CR23","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/j.jid.2018.12.032","volume":"139","author":"J Takeshita","year":"2019","unstructured":"Takeshita J, Eriksen WT, Raziano VT et al (2019) Racial differences in perceptions of psoriasis therapies: implications for racial disparities in psoriasis treatment. J Invest Dermatol 139(8):1672-1679.e1. https:\/\/doi.org\/10.1016\/j.jid.2018.12.032","journal-title":"J Invest Dermatol"},{"key":"3623_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.02.013","author":"J Takeshita","year":"2022","unstructured":"Takeshita J, Augustin M, de Jong EMGJ et al (2022) Health-related QOL differs by race\/ethnicity in North American patients with psoriasis: results from PSOLAR. J Invest Dermatol. https:\/\/doi.org\/10.1016\/j.jid.2022.02.013","journal-title":"J Invest Dermatol"},{"issue":"11","key":"3623_CR25","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1007\/s13555-022-00811-0","volume":"12","author":"G Yadav","year":"2022","unstructured":"Yadav G, Yeung J, Miller-Montrhope Y et al (2022) Unmet need in people with psoriasis and skin of color in Canada and the United States. Dermatol Ther 12(11):2401\u20132413. https:\/\/doi.org\/10.1007\/s13555-022-00811-0","journal-title":"Dermatol Ther"},{"issue":"2","key":"3623_CR26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1001\/jamadermatol.2016.4129","volume":"153","author":"A Charrow","year":"2017","unstructured":"Charrow A, Xia FD, Joyce C, Mostaghimi A (2017) Diversity in dermatology clinical trials: a systematic review. JAMA Dermatol 153(2):193\u2013198. https:\/\/doi.org\/10.1001\/jamadermatol.2016.4129","journal-title":"JAMA Dermatol"},{"issue":"2","key":"3623_CR27","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/bjd.19468","volume":"184","author":"VD Reddy","year":"2021","unstructured":"Reddy VD, Myers BA, Chan SY et al (2021) A review of current phase III clinical trials of plaque psoriasis: under-representation of nonwhite participants and need for reform. Br J Dermatol 184(2):348\u2013350. https:\/\/doi.org\/10.1111\/bjd.19468","journal-title":"Br J Dermatol"},{"issue":"3","key":"3623_CR28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40257-014-0064-x","volume":"15","author":"LF Sandoval","year":"2014","unstructured":"Sandoval LF, Pierce A, Feldman SR (2014) Systemic therapies for psoriasis: an evidence-based update. Am J Clin Dermatol 15(3):165\u2013180. https:\/\/doi.org\/10.1007\/s40257-014-0064-x","journal-title":"Am J Clin Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03623-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03623-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03623-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T10:03:54Z","timestamp":1733997834000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03623-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3623"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03623-8","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,12]]},"assertion":[{"value":"15 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This is a retrospective observational study, so no ethics approval is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"106"}}